David Novak analyst STIFEL

Currently out of the existing stock ratings of David Novak, 17 are a BUY (100%).

David Novak

Work Performance Price Targets & Ratings Chart

Analyst David Novak works at STIFEL with a stock forecast success ratio of 50% fulfilled within 228.5 days on average. Previously, David Novak worked at RAYMOND JAMES.

David Novak’s has documented 31 price targets and ratings displayed on 6 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ZYME, Zymeworks . Common Stock at 10-Dec-2021.

Wall Street Analyst David Novak

Analyst best performing recommendations are on ZYME (ZYMEWORKS . COMMON STOCK).
The best stock recommendation documented was for ZYME (ZYMEWORKS . COMMON STOCK) at 10/1/2019. The price target of $40 was fulfilled within 52 days with a profit of $14.91 (59.43%) receiving and performance score of 11.43.

Average potential price target upside

CBIO Catalyst Biosciences ZYME Zymeworks . Common Stock LPTX Leap Therapeutics TCRT Alaunos Therapeutics ZIOP ZIOPHARM Oncology MEDXF Medexus Pharmaceuticals

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

3

$-4.67 (-60.89%)

4

1 years 11 months 26 days ago

2/5 (40%)

$1.92 (177.78%)

220

Hold

2 years 4 months 12 days ago

0/1 (0%)

$10.5 (123.53%)

Buy

24

$23.52 (4900.00%)

5 years 2 months 24 days ago

0/1 (0%)

$18.19 (313.08%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by David Novak?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?